US FDA Approves FoundationOne®CDx and FoundationOne®Liquid CDx as Companion Diagnostics for TALZENNA® (talazoparib) in Combination with XTANDI® (enzalutamide) to Identify Patients with HRR ...
New data with longer-term follow-up suggest that PSA screening probably lowers prostate cancer mortality — but experts stress ...
Editor's note: Dr. Jamin Brahmbhatt is a urologist and robotic surgeon with Orlando Health and an assistant professor at the University of Central Florida’s College of Medicine.When I learned that ...
Wolinsky is a Chicago-based medical journalist and publisher of The Active Surveillor, a Substack newsletter that covers lower-risk prostate cancer and active surveillance. In 2002, at age 55, I ...
"ASCO26: Talzenna and Xtandi combo has first-line promise in HRR altered-mCSPC" was originally created and published by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results